Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) EPS (Basic) (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed EPS (Basic) for 12 consecutive years, with -$1.46 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Basic) fell 114.71% year-over-year to -$1.46; the TTM value through Mar 2026 reached -$5.9, down 436.36%, while the annual FY2025 figure was -$5.02, 12.05% down from the prior year.
  • EPS (Basic) hit -$1.46 in Q1 2026 for Cartesian Therapeutics, up from -$3.57 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.58 in Q2 2024 and bottomed at -$41.56 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$3.94, with a median of -$1.13 recorded in 2024.
  • Year-over-year, EPS (Basic) skyrocketed 204.55% in 2022 and then plummeted 138633.33% in 2023.
  • Cartesian Therapeutics' EPS (Basic) stood at $0.03 in 2022, then tumbled by 138633.33% to -$41.56 in 2023, then soared by 100.31% to $0.13 in 2024, then crashed by 2846.15% to -$3.57 in 2025, then skyrocketed by 59.1% to -$1.46 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$1.46, -$3.57, and -$1.38 for Q1 2026, Q4 2025, and Q3 2025 respectively.